Oncology Corporate Profile
EKK-TEC was formed in 1983, and has utilized government and private funding to effectively develop new therapies and clinical development candidates for the treatment of cancer, pre-cancerous lesions, and women's health issues. We have previously licensed two of our pipeline products to Biotech/Pharmaceutical companies who have successfully driven these compounds into Phase II clinical development. We also have experience with 510K devise submissions. Our present objective is to continue to create and develop new and novel drugs based on our current novel cancer therapeutic agents - DM-CHOC-PEN and hydroperoxy analogs.